CD20阴性的弥漫大B细胞淋巴瘤的研究进展  

Research progress of CD20 negative diffuse large B cell lymphoma

作　　者：孙梦琪[1] 赵曙[1] 张清媛[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院肿瘤内科,哈尔滨150081

出　　处：《临床肿瘤学杂志》2017年第5期461-464,共4页Chinese Clinical Oncology

摘　　要：CD20阴性的弥漫大B细胞淋巴瘤是一种罕见的异质性淋巴增生性疾病。其以化学免疫治疗耐药性及低生存率为特点,表现为不典型的细胞形态和侵袭性的临床行为,因此CD20阴性弥漫大B细胞淋巴瘤的诊疗都是个难题。本综述分别对不同类型CD20阴性弥漫大B细胞淋巴瘤的临床特征、预后及治疗进行介绍,以提高临床医生对于此类恶性肿瘤的认识,从而提升其疗效。The CD20-negative diffuse large B-cell lymphoma （DLBCL） is a rare and heterogeneous group of lymphoproliferative disorders.Given the lack of CD20 expression, atypical cellular morphology and aggressive clinical behavior characterized by chemotherapy resistance and inferior survival rates, CD20-negative DLBCL represented a challenge from the diagnostic and therapeutic perspectives.This review introduces the clinical characteristics, prognosis and treatment of different types of CD20-negative DLBCL to improve clinicians awareness for this kind of malignancy and to enhance its therapeutic effect.

关 键 词：弥漫大B细胞淋巴瘤 CD20阴性 浆母细胞淋巴瘤 原发性渗出性淋巴瘤 

分 类 号：R733[医药卫生—肿瘤]